Advances in Hodgkin Lymphoma: Including the Patient’s Voice

Smith, Christine M.; Friedman, Debra L.

doi:10.3389/fonc.2022.855725

Cited by 3 publications

(2 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the US Food and Drug Administration and European Medicines Agency, recommend PROs as a prioritized treatment outcome ( 26 , 27 ). Indeed, the added value of including PROs in clinical trials of HL patients has previously been reported ( 28 – 30 ). Data derived from PRO assessment can provide the patient-level impact of regimens on event-free survival, overall survival, and tolerability of the acute as well as the long-term effects of treatment.…”

Section: Introductionmentioning

confidence: 95%

“…It is also important to note that improvement in QoL is included in the European Society of Medical Oncology Magnitude of Clinical Benefit Scale to determine the “value” of novel therapeutic options in cancer ( 31 – 33 ). Several systematic reviews on the use of PROs in clinical trials in the HL setting have previously been published ( 29 , 30 , 34 ). However, for trials involving HL patients, it still is unclear as to which PRO instruments are used, frequency of their use, and whether their results are consistently reported.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review

Oliva,

Ionova,

Laane

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundLymphoma treatment can lead to long-term consequences such as fatigue, infertility and organ damage. In clinical trials, survival outcomes, clinical response and toxicity are extensively reported while the assessment of treatment on quality of life (QoL) and symptoms is often lacking.ObjectiveWe evaluated the use and frequency of patient-reported outcome (PRO) instruments used in randomized controlled trials (RCTs) for Hodgkin lymphoma (HL) and their consistency of reporting.MethodsMEDLINE, CENTRAL and trial registries for RCTs investigating HL were systematically searched from 01/01/2016 to 31/05/2022. Following trial selection, trial, patient characteristics and outcome data on the use of PRO measures (PROMs) and reporting of PROs using a pre-defined extraction form were extracted. To assess reporting consistency, trial registries, protocols and publications were compared.ResultsWe identified 4,222 records. Following screening, a total of 317 reports were eligible for full-text evaluation. One hundred sixty-six reports of 51 ongoing/completed trials were included, of which 41% of trials were completed and 49% were ongoing based on registry entries. Full-text or abstract were available for 33 trials. Seventy percent of trials were conducted in the newly diagnosed disease setting, the majority with advanced HL. In 32 trials with published follow-up data, the median follow-up was 5.2 years. Eighteen (35%) completed/ongoing trials had mentioned PRO assessment in registry entries, protocol or publications. Twelve trials (67%) had published results and only 6 trials (50%) reported on PROs in part with the exception of 1 trial where PROs were evaluated as secondary/exploratory outcome. The most referenced global PROM was the EORTC-QLQ-C30 (12 studies), the EQ-5D (3 studies) and the FACT-Neurotoxicity (3 studies). FACT-Lymphoma, a disease-specific PROM for non-HL was mentioned in one ongoing trial. None of the trials referenced the EORTC QLQ-HL27, another disease-specific PROM developed specifically for HL patient’s QoL assessment.DiscussionsOnly one-third of RCTs in HL report PROs as an outcome and only half present the outcome in subsequent publications, showcasing the underreporting of PROs in trials. Disease-specific PROMs are underutilized in the assessment of QoL in HL patients. Guidance on the assessment of PROs is needed to inform on comprehensive outcomes important to patients.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=391552, identifier CRD42023391552.

show abstract

Section: Introductionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review

Oliva,

Ionova,

Laane

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape

Ebrahimi,

Habibzadeh,

Khojasteh-Kaffash

et al. 2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma

et al. 2023

View full text Add to dashboard Cite

BackgroundPediatric classical Hodgkin lymphoma (CHL) is a curable disease; however, the optimal salvage regimen is unclear for relapsed/refractory (R/R) disease. This study aimed to compare response rates, toxicity, event-free survival (EFS), and overall survival (OS) of ifosfamide, carboplatin, and etoposide (ICE) with gemcitabine and vinorelbine (GV) regimen after first-line doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) in pediatric patients with R/R CHL.MethodsThis is a retrospective cohort study of 132 pediatric patients with R/R CHL treated from July 2012 to December 2020 with ICE (n = 82) or GV (n = 50).ResultsThe median age at relapse was 13.9 years, and 68.2% were men. Rates of complete response, partial response, and progressive disease before consolidation were 50.6%, 3.7%, and 45.7% for ICE and 28.5%, 0%, and 71.5% for GV (P = 0.011). By multivariate analysis, regimen (P = 0.002), time to relapse (P = 0.0001), and B-symptoms (P = 0.002) were independent factors to lower response rates. Hematological toxicity, electrolyte disturbance, hemorrhagic cystitis, infectious complications, and hospital admission for fever neutropenia were statistically significant higher for the ICE regimen. Treatment-related mortalities were 2.4% for ICE and 2% for GV (P = 0.86). The 3-year EFS was 39.3% ± 11.4% for ICE and 24.9% ± 12.5% for GV (P = 0.0001), while 3-year OS was 69.3% ± 10.6% and 74% ± 12.9% (P = 0.3), respectively. By multivariate analysis, regimen (P = 0.0001), time to relapse (P = 0.011), B-symptoms (P = 0.001), and leukocytosis (P = 0.007) were significant for EFS, while anemia (P = 0.008), and progressive disease on early response evaluation (P = 0.022) were significant for OS.ConclusionsThe ICE regimen had a better overall response rate and EFS, but higher toxicity, than GV; however, OS and mortality were similar.

show abstract

Advances in Hodgkin Lymphoma: Including the Patient’s Voice

Cited by 3 publications

References 65 publications

Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review

Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review

Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma

Contact Info

Product

Resources

About